- Home
- NBIX vs EHC Comparison
NBIX vs EHC Comparison
Compare NBIX & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- EHC
- Stock Information
- Founded
- NBIX 1992
- EHC 1983
- Country
- NBIX United States
- EHC United States
- Employees
- NBIX N/A
- EHC N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- EHC Hospital/Nursing Management
- Sector
- NBIX Health Care
- EHC Health Care
- Exchange
- NBIX Nasdaq
- EHC Nasdaq
- Market Cap
- NBIX 14.4B
- EHC 12.4B
- IPO Year
- NBIX 1996
- EHC 1986
- Fundamental
- Price
- NBIX $147.21
- EHC $116.15
- Analyst Decision
- NBIX Strong Buy
- EHC Strong Buy
- Analyst Count
- NBIX 18
- EHC 8
- Target Price
- NBIX $172.33
- EHC $141.88
- AVG Volume (30 Days)
- NBIX 1.1M
- EHC 910.8K
- Earning Date
- NBIX 10-28-2025
- EHC 10-29-2025
- Dividend Yield
- NBIX N/A
- EHC 0.65%
- EPS Growth
- NBIX 12.44
- EHC 27.89
- EPS
- NBIX 4.19
- EHC 5.29
- Revenue
- NBIX $2,682,700,000.00
- EHC $5,795,600,000.00
- Revenue This Year
- NBIX $23.68
- EHC $11.54
- Revenue Next Year
- NBIX $18.02
- EHC $8.79
- P/E Ratio
- NBIX $35.13
- EHC $21.97
- Revenue Growth
- NBIX 19.61
- EHC 11.13
- 52 Week Low
- NBIX $84.23
- EHC $87.85
- 52 Week High
- NBIX $157.67
- EHC $127.99
- Technical
- Relative Strength Index (RSI)
- NBIX 54.30
- EHC 37.20
- Support Level
- NBIX $133.62
- EHC $111.47
- Resistance Level
- NBIX $157.67
- EHC $116.21
- Average True Range (ATR)
- NBIX 5.20
- EHC 3.73
- MACD
- NBIX 0.58
- EHC -0.75
- Stochastic Oscillator
- NBIX 56.13
- EHC 41.38
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.